Infections and infestations: Herpetic keratitis*.
Nervous system disorders: Dizziness*; headache*.
Eye disorders: Eye irritation (burning, grittiness, itching, stinging and foreign body sensation); eye pain; eyelash and vellus hair changes of the eyelid (increased length, thickness, pigmentation, and number of eyelashes)*; ocular hyperaemia; iris hyperpigmentation; blepharitis; conjunctivitis*; macular oedema including cystoid macular oedema*; photophobia*; eyelid oedema; keratitis*; uveitis*; corneal oedema*; iritis*; punctate keratitis*; corneal erosion*; trichiasis*; vision blurred*; periorbital and lid changes resulting in deepening of the eyelid sulcus*; darkening of the palpebral skin of the eyelids*; localised skin reaction on the eyelids*; iris cyst* pseudopemphigoid of ocular conjunctiva*.
Cardiac disorders: Angina; palpitations*; angina unstable*.
Respiratory, thoracic and mediastinal disorders: Asthma*; dyspnoea*; asthma aggravation*; acute asthma attacks*.
Skin and subcutaneous tissue disorders: Rash; pruritus.
Musculoskeletal and connective tissue disorders: Myalgia*; arthralgia*.
General disorders and administration site conditions: Chest pain*.
*ADR identified post-marketing.
Adverse reactions reported with the use of eye drops containing phosphate buffers: Cases of corneal calcification have been reported very rarely in association with the use of phosphate-containing eye drops in some patients with significantly damaged corneas.